Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Aug;4(4):33-42.

Demonstrating the value of biologics: a call to action

Jeff Clough  1
Affiliations

Demonstrating the value of biologics: a call to action

Jeff Clough. Biotechnol Healthc. 2007 Aug.

Abstract

Efforts to control spending on biologics have been fragmented and inconsistent, and quality information to guide the way is scarce. How can coverage decisions be made without wasting valuable healthcare dollars, while still encouraging new development in therapies?

PubMed Disclaimer

Figures

None
Jeff Clough
See this image and copyright information in PMC

References

    1. Adams KT. The off-label conundrum. Biotechnol Healthcare. 2006;3:27–34. - PMC - PubMed
    1. Anand G. The most expensive drugs. Wall Street Journal. 2005 Nov 15;:A1.
    1. BIO (Biotechnology Industry Organization) Approved Biotechnology Drugs. « http://www.bio.org/speeches/pubs/er/approveddrugs.asp». Accessed July 10, 2007.
    1. Butcher L. Newly final CMS policy may help plans when evidence for coverage is lacking. Biotechnol Healthcare. 2006;3:41–45. - PMC - PubMed
    1. Carino T, Williams RD, Colbert AM, Bridger P. Medicare’s coverage of colorectal cancer drugs: a case study in evidence development and policy. Health Aff (Millwood) 2006;25:1231–1239. - PubMed

Further reading

    1. Arseneau KO, Cohn SM, Cominelli F, Connors AF., Jr Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology. 2001;120:1640–1656. - PubMed
    1. Bodger K. Economic implications of biological therapies for Crohn’s disease: review of infliximab. Pharmacoeconomics. 2005;23:875–888. - PubMed
    1. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648. - PubMed
    1. Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn’s disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care. 2004;20:274–279. - PubMed
    1. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994;9:1829–1838. - PubMed

LinkOut - more resources